OncoMatch/Clinical Trials/NCT05430009

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Is NCT05430009 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Pembrolizumab for liver metastases.

Phase 1RecruitingVA Ann Arbor Healthcare SystemNCT05430009Data as of May 2026

Treatment: Pembrolizumab — Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function per protocol.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Veterans Affairs Ann Arbor Healthcare System · Ann Arbor, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify